after hours with the research
CJC-1295 is a long-acting GHRH analog studied for multi-day growth-hormone release.
A late-edition reading of the published record — what the human pharmacokinetics actually showed, why it is paired with ipamorelin, and where the DAC and no-DAC stories split the molecule in two.
What CJC-1295 is
CJC-1295 is a synthetic, long-acting analog of growth-hormone-releasing hormone (GHRH). It is built on the first 29 residues of human GH-releasing factor, hGRF(1-29), and carries four amino-acid substitutions — D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27 — that stabilize the helix and block the protease dipeptidylpeptidase-IV from cleaving it [1]. In the DAC ("Drug Affinity Complex") variant a C-terminal lysine carries a maleimide handle that bonds covalently to circulating serum albumin, dragging the molecule's plasma half-life toward that of albumin itself [1].
The result is unusual for a peptide: in healthy adults, single subcutaneous doses of 30 or 60 micrograms per kilogram raised mean plasma growth hormone 2- to 10-fold for six days or more, and IGF-1 1.5- to 3-fold for nine to eleven days, with an estimated half-life of 5.8-8.1 days [2]. That is the whole reason this molecule has a name. Most GHRH peptides are gone in minutes; CJC-1295 with DAC is measured in days.
This site is not a clinic and not a store. It reads the published human research on CJC-1295 straight, logs every number to its study, and keeps the DAC-versus-no-DAC distinction in plain view — because the marketplace routinely blurs it.
CJC-1295 as a research peptide
Treated honestly, CJC-1295 is a research peptide, not a therapy. It has no approved human indication anywhere in the world and is handled as a research chemical [9]. The peer-reviewed human evidence is a short shelf: two early Phase 1 pharmacokinetic studies in healthy volunteers established the GH and IGF-1 kinetics [2][3], and a later proteomics paper traced the axis it activates [5]. A ConjuChem Phase 2 trial in HIV-associated visceral obesity (NCT00267527) was discontinued, and the long-acting DAC program did not advance [9].
As a peptide it is not orally active — bioavailability by mouth is negligible — so every route in the literature is injected, subcutaneous primarily, intravenous in the earliest GRF(1-29) work [9]. It is also prohibited at all times in sport under Section S2 of the WADA Prohibited List, and assays to detect it by mass spectrometry are well established [6][9].
What follows is the record, not a recommendation: the doses used in research, the mechanism, and the common questions about CJC-1295.
The two stories that define the molecule
Two threads run through everything written about CJC-1295, and both are easy to get wrong.
The first is the pairing. A GHRH analog drives the pituitary through the GHRH receptor; a growth-hormone-releasing peptide (GHRP) such as ipamorelin drives it through a different receptor entirely. Give both, and the growth-hormone release is greater than the sum of either alone [7]. That two-pathway logic is why the CJC-1295 and ipamorelin synergy is the most-searched form of the compound — and why the research behind it deserves to be read carefully rather than copied off a forum.
The second is the half-life. "CJC-1295" is two molecules wearing one name. The DAC variant binds albumin and acts for days; the no-DAC form, "Modified GRF 1-29," keeps the four substitutions but has no albumin handle and is short-acting [1]. They are pharmacokinetically different drugs. The CJC-1295 DAC vs no-DAC page keeps them apart, because most marketing does not.
How to read this site
Every quantitative claim here — every dose, percentage, duration, half-life and n-value — is keyed to a numbered citation, and the originals are gathered in the reference list. The strongest results sit on /research; the pharmacokinetics live on /dac-vs-no-dac; the pairing rationale is on /ipamorelin-synergy.
Where the evidence is thin, this site says so plainly rather than filling the gap. There are no controlled efficacy trials of the CJC-1295/ipamorelin combination in healthy adults, no long-term safety data, and no validated human dose [9]. Those are not omissions; they are the findings. CJC-1295 is a GHRH analog overview worth understanding precisely — and precision means naming what the literature has not yet measured.